Evidence map›Paper›PMID 42892656›Full record

ArticleAmino acids2026

Difluoromethylornithine modulates mutant K-RAS signaling pathways in pancreatic cancer cells.

Hwudaurw Chen, David E Stringer, Haiyan Cui, Eugene W Gerner, Natalia A Ignatenko

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Amino acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hwudaurw ChenUniversity of Arizona Cancer Center, Tucson, AZ, USA.
David E StringerUniversity of Arizona Cancer Center, Tucson, AZ, USA.
Haiyan CuiUniversity of Arizona Cancer Center, Tucson, AZ, USA.
Eugene W GernerDepartment of Cellular & Molecular Medicine, University of Arizona, Tucson, AZ, USA.
Natalia A IgnatenkoUniversity of Arizona Cancer Center, Tucson, AZ, USA. nai@arizona.edu.ORCID https://orcid.org/0000-0002-8096-1340

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
Role of Kallikrein 6 expression and secretion in colon cancerR01CA157595 · NCI · UNIVERSITY OF ARIZONA · PI IGNATENKO, NATALIA A · 2012 to 2016
$1.7M
NCI NIH HHS P30 CA023074NCI NIH HHS R01 CA157595NCI NIH HHS R01CA157595; P30CA023074 (Cancer Center Support Grant)
6 · The paper itself

Abstract

Oncogenic mutations in the K-RAS small GTPase occur in more than 90% of human PDACs and cause dysregulation of multiple metabolic pathways, including polyamine metabolism. The goal of this study was to determine whether blocking polyamine synthesis with the irreversible inhibitor α-difluoromethylornithine (DFMO) provides a valid approach to targeting metabolic dependency in mutant K-RAS pancreatic tumors, compared with direct suppression of the oncogenic K-RAS protein. The anti-tumor activity of DFMO was evaluated in vitro and in vivo in the MIA PaCa-2 pancreatic cell line (K-RAS

Indexed as

Antineoplastic AgentsEflornithinePancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Signal TransductionAnimalsCell Line, TumorHumansMiceMutationPolyaminesras ProteinsXenograft Model Antitumor AssaysAntineoplastic AgentsEflornithineKRAS protein, humanPolyaminesProto-Oncogene Proteins p21(ras)ras ProteinsDifluoromethylornithineHypusinated eIF5APancreatic adenocarcinomaPancreatic orthotopic mouse modelPolyaminesRAS-like small GTPase A

Identifiers

PMID42892656
PMCPMC13676551

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.